ABSTRACT
The aim of this study was to determine the efficacy of hepatitis B virus (HBV) vaccination and the response to vaccine in individuals on haemodialysis with and without HCV infection. From April 2000 to September 2003 all haemodialysis patients referred to the haemodialysis department in a Babol hospital received 4 microg vaccine intramuscularly at 0, 1, and 6 months. All were negative for HBV infection markers (HBcAb, HBsAg and HBsAb). Of 62 patients, 53 (85.5%) responded to vaccination and 26 (49.1%) were high responders. All individuals with HCV infection responded to vaccination. Duration of haemodialysis had no effect on response to vaccination.
Subject(s)
Hepatitis B Vaccines , Hepatitis B/prevention & control , Hepatitis C/complications , Renal Dialysis , Vaccination , Adult , Case-Control Studies , Chi-Square Distribution , Enzyme-Linked Immunosorbent Assay , Female , Hepatitis B/blood , Hepatitis B/complications , Hepatitis B/immunology , Hepatitis B Antibodies/blood , Hepatitis B Core Antigens/blood , Hepatitis B Surface Antigens/blood , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/immunology , Hepatitis C/blood , Hepatitis C/immunology , Hepatitis C Antibodies/blood , Humans , Immunization Schedule , Iran , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Male , Middle Aged , Renal Dialysis/adverse effects , Vaccination/methodsABSTRACT
The aim of this study was to determine the efficacy of hepatitis B virus [HBV] vaccination and the response to vaccine in individuals on haemodialysis with and without HCV infection. From April 2000 to September 2003 all haemodialysis patients referred to the haemodialysis department in a Babol hospital received 4 microg vaccine intramuscularly at 0, 1, and 6 months. All were negative for HBV infection markers [HBcAb, HBsAg and HBsAb]. Of 62 patients, 53 [85.5%] responded to vaccination and 26 [49.1%] were high responders. All individuals with HCV infection responded to vaccination. Duration of haemodialysis had no effect on response to vaccination
Subject(s)
Renal Dialysis , Hepatitis C , Enzyme-Linked Immunosorbent Assay , Hepatitis C Antibodies , Hepatitis B VaccinesABSTRACT
Growth retardation in children with chronic kidney disease (CKD) is multifactorial that include inadequate protein and calorie intake, persistent metabolic acidosis, calcitriol deficiency, renal osteodystrophy, drug toxicity, uremic toxins and growth factor abnormalities such as insulin-like growth factor (IGF) and IGF binding proteins. In this study, we compare the IGF-1 levels in normal and growth retarded CKD children. Serum IGF-1 levels were determined in 22 children with end-stage renal disease, 26 children with CKD at different stages, 23 children with normal height and weight for age and 23 children with constitutionally short stature. Mean serum levels of IGF-1 were 209 +/- 141 ng/ml in the ESRD group (group 1), 159 +/- 163 ng/ml in the CKD group (group 2), 420 +/- 182 ng/ml in normal children (group 3) and 360 +/- 183 ng/ml in children with constitutional short stature (group 4). The differences in the levels of IGF-1 in groups 1 and 2 were statistically significant when compared to groups 3 and 4 (p< 0.0001 and p< 0.02, respectively), while the levels of IGF-1 were not statistically different between groups 1 and 2. No correlation was found between IGF-1 levels and glomerular filtration rate, height or weight in groups 1 and 2. In conclusion, serum levels of IGF-1 in children with CKD are significantly lower than healthy children.